A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and
Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.